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Abstract
Although anticapsular antibodies confer serotype-specific immunity to pneumococci, children increase their ability to clear
colonization before these antibodies appear, suggesting involvement of other mechanisms. We previously reported that
intranasal immunization of mice with pneumococci confers CD4+ T cell–dependent, antibody- and serotype-independent
protection against colonization. Here we show that this immunity, rather than preventing initiation of carriage, accelerates
clearance over several days, accompanied by neutrophilic infiltration of the nasopharyngeal mucosa. Adoptive transfer of
immune CD4+ T cells was sufficient to confer immunity to naı¨ve RAG12/2 mice. A critical role of interleukin (IL)-17A was
demonstrated: mice lacking interferon-c or IL-4 were protected, but not mice lacking IL-17A receptor or mice with
neutrophil depletion. In vitro expression of IL-17A in response to pneumococci was assayed: lymphoid tissue from
vaccinated mice expressed significantly more IL-17A than controls, and IL-17A expression from peripheral blood samples
from immunized mice predicted protection in vivo. IL-17A was elicited by pneumococcal stimulation of tonsillar cells of
children or adult blood but not cord blood. IL-17A increased pneumococcal killing by human neutrophils both in the
absence and in the presence of antibodies and complement. We conclude that IL-17A mediates pneumococcal immunity in
mice and probably in humans; its elicitation in vitro could help in the development of candidate pneumococcal vaccines.
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Introduction
Streptococcus pneumoniae (pneumococcus) is an ‘‘extracellular’’
pathogen, generally considered to be killed by phagocytic ingestion,
which is facilitated by opsonic antibodies. The success of anti-
pneumococcal serum therapy using passive transfer of serotype-
specific antibodies [1] and of vaccinations based on purified or
conjugated capsular antigens [2,3] clearly shows that anticapsular
antibodies protect humans against pneumococcal colonization and
disease. There is good epidemiologic evidence for the importance of
such immunity in certain common serotypes [4,5]. However, we and
others have found that factors other than anticapsular antibodies may
play a role in the natural development of protection against
pneumococcal colonization and disease. First, the reduction in
pneumococcal disease incidence after the first year of life occurs
simultaneously for both rare and common serotypes, suggesting the
acquisition of one rather than many individual immune responses [6].
Similarly, the duration of carriage of many serotypes declines steeply
between the first and second birthdays for many serotypes [7]. Since
experience with conjugate vaccines has suggested that anticapsular
antibodies reduce incidence of carriage but leave duration unaffected
[8], this observation also suggests a mechanism of acquired immunity
other than anticapsular antibodies. Moreover, the declines in carriage
duration and invasive disease incidence precede by several years the
detection of naturally-acquired anticapsular antibody in most
children [6,7]. Experimental [9,10] and observational [4,11] studies
in adults have found little or no evidence that higher anticapsular
antibody concentrations are associated with greater protection from
colonization. Pneumococci also express non-capsular antigens
common among serotypes, and certain of these have been found to
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elicit antibodies with protective potential in animal models. The role
of such antibodies in human immunity has been evaluated
[12,13,14,15,16,17].
Surprisingly however, recent studies have shown that immunity
in mice to pneumococcal colonization acquired from prior
exposure to live bacteria [18] or a killed, whole-cell vaccine
[WCV, consisting of killed pneumococcal whole cell antigen
(WCA) with cholera toxin (CT) as an adjuvant] [19] is
independent of antibodies of any specificity, and clearance of
longstanding carriage in previously unexposed animals can
likewise be antibody-independent [20]. Immunity had been shown
to be dependent on the presence of CD4+ T cells at the time of
challenge [18,19], but the co-participation of specific immune
factors other than antibody was not ruled out.
Here we show that intranasal immunization with the WCV
confers protection against experimental pneumococcal coloniza-
tion via the chemoattractant and neutrophil activating cytokine
IL-17A, in a neutrophil-dependent fashion. Methods were devised
to assay expression of IL-17A in vitro using peripheral blood
samples. IL-17A expression by peripheral blood of WCV-
immunized mice is highly correlated with subsequent protection
against colonization, and expression by human cells, including
those from adults and children, can be shown as well. Finally, we
developed a surface phagocytosis assay with which we show that
IL-17A enhances pneumococcal killing by human polymorpho-
nuclear cells in the absence as well as presence of opsonins.
The data indicate the possibility that IL-17A responses play a role
in naturally-acquired immunity to pneumococcus in humans and that
assay of this cytokine in vitro may assist in the evaluation of certain
candidate pneumococcal vaccines that target mucosal colonization.
Results
Prior exposure of mice to killed or live pneumococci
reduces the duration of experimental pneumococcal
carriage
The duration of carriage was followed after intranasal challenge
with serotype 6B pneumococci 4 weeks post-exposure to WCV.
Both WCV-vaccinated and control mice immunized with CT
alone were colonized one day after challenge. In mice immunized
with WCV however, carriage became significantly reduced after 4
days compared to controls given cholera toxin (CT) adjuvant alone
(median density of colonization on day 4 in WCV- vs. CT-
immunized mice 251 vs. 3720 cfu/nasal wash, P = 0.029 by
Mann-Whitney U test) and was undetectable by day 6 (0/4 WCV-
immunized mice had detectable colonies on day 6 vs. 4/4 mice
that received CT, P = 0.029 by Fisher’s Exact test, Figure 1A). A
similar differential was observed in mice that had been repeatedly
exposed to live pneumococci vs. saline controls: the density of
colonization became significantly different by day 4 after
inoculation (Figure 1A). By day 6, similar to what we observed
in WCV-immunized mice, 0/4 mice exposed to live pneumococci
had detectable colonies compared to 4/4 saline controls (P = 0.029
by Fisher’s exact test). When data from all time points were
Figure 1. Duration of carriage and effect of adoptive transfer
following immunization with killed or live pneumococci. A.
Effect of intranasal immunization with WCV or live exposure upon
density of pneumococcal colonization in C57BL/6 mice. Density of
colonization in mice immunized with WCV vs. CT alone or repeatedly
exposed to live pneumococcal strain 0603 vs. saline alone at various
time points (n = 4 per time point) following challenge. By day 4, both
the incidence and density of carriage were significantly lower in mice
immunized with WCV or exposed to live pneumococcus compared to
mice immunized with CT or saline, respectively. * P,0.05. The dashed
line represents the lower limit of detection of bacterial colonization. B.
Effect of adoptive transfer of CD4+ T cells from WCV-immunized mice
on pneumococcal colonization of recipient, unimmunized RAG12/2
mice. Each data point represents the density of nasopharyngeal
colonization in cfu/ nasal wash for each mouse one week post-
challenge. The horizontal bar shows the geometric mean cfu/nasal
wash for each group and the dashed line represents the lower limit of
detection of bacterial colonization. C57BL/6 mice were immunized with
WCV or CT as indicated. Four weeks after the last immunization, CD4+ T
cells were harvested from splenocytes of mice and infused into naı¨ve,
unimmunized RAG12/2 mice; challenge of these mice and quantifica-
tion of colonization was then performed. RAG12/2 mice that received
CD4+ T cells from WCV-immunized mice had significantly lower density
of colonization than mice that received cells from CT-immunized mice
(*** P,0.0001 by Mann-Whitney U).
doi:10.1371/journal.ppat.1000159.g001
Author Summary
The bacterium Streptococcus pneumoniae (pneumococcus)
causes serious disease in children and the elderly,
including pneumonia and meningitis (inflammation of
the brain). Carriage of pneumococcus in the nose is a
necessary first step for most infections. As children age,
they carry pneumococcus for shorter periods of time and
their risk of disease decreases also. The mechanisms
underlying this age-related decrease of carriage are not
well understood. A deeper understanding of resistance to
colonization would enable us to develop better pneumo-
coccal vaccines. Using experimental mouse models, we
show that repeated exposure to pneumococci leads to a
subsequent reduction in duration of pneumococcal
carriage, similar to what is observed in humans. We
identify the immune cells that are responsible for this
process, so-called TH17 cells, which release a factor that
enables human blood cells to kill pneumococcus more
efficiently. We show that these TH17 cells exist in adults
and children, but not in newborn babies, which suggests
that they may arise as a consequence of humans being
exposed to pneumococcus. We describe an assay for the
measurement of these cells in humans. Such an assay
could facilitate the development of novel vaccines
directed against pneumococcal carriage.
IL-17A and Pneumococcal Colonization
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compared, mice immunized with WCV or exposed to live
pneumococci had a significantly shorter time to clearance
compared to their respective CT or saline controls (P = 0.0001
for comparison of WCV vs. CT and P = 0.004 for comparison of
live exposure vs. saline). Thus the protection by prior pneumo-
coccal exposure involves not immediate blockage of colonization
but rather an accelerated clearance over days. Subsequent studies
compared WCV-vaccinated with control animals 7 days after the
intranasal challenge.
CD4+ T cells transfer acquired immunity to
pneumococcal colonization to RAG12/2 mice
Several previous studies showed that acquired immunity to
pneumococcal colonization in mice can be antibody-independent
and dependent on CD4+ T cells [19,20,21,22]. Here, adoptive
transfer showed that CD4+ T cells are not only necessary but also
sufficient for the accelerated clearance induced by WCV:
unimmunized Rag12/2 mice (lacking both B and T cells) were
infused with CD4+ T cells from mice immunized with WCV or
CT alone. The RAG12/2 mice that received CD4+ T cells from
WCV-immunized wild-type mice had significantly reduced density
of colonization by day 7 compared to mice infused with CD4+ T
cells from mice immunized with CT alone (P = 0.0001 by Mann-
Whitney U, Figure 1B).
Acquired immunity to pneumococcal colonization is
associated with the TH17 subset of CD4+ T cells
To evaluate which CD4+ T cell subset is responsible for
protection, IFN-c, IL-4 or IL-17A receptor (IL-17AR) knockout
mice were immunized with WCV vs. CT alone. IFN- c- and IL-4-
deficient mice immunized with WCV were significantly protected
against colonization both with respect to proportion of colonized
mice (P,0.001 by Fisher’s Exact test for comparison of % of
colonization in WCV- and CT-immunized IFN-c- or IL-4-
deficient mice) and density of colonization (P#0.001 compared
to their respective CT controls, Figure 2A). In contrast, mice with
a targeted deletion of the IL-17A receptor were not protected
(P.0.5 vs. CT controls for % colonized mice or density of
colonization, Figure 2A). It is noteworthy that IL-17AR-knockout
mice in the CT control group had, on average, a ten-fold greater
density of colonization than the corresponding IFN-c or IL-4
deficient mice, suggesting that IL-17A may also be involved in
resistance to colonization in naı¨ve mice.
Splenocytes from mice immunized with WCV expressed
significantly more IL-17A in response to WCA in vitro than cells
from CT control animals (Figure 2B). We have previously shown
that immunization with WCV confers protection against NP
colonization in a CD4+ T cell dependent fashion [19]; additional
experiments were performed here to confirm that IL-17A is
produced by CD4+ T cells. Depletion of CD4+ T cells effectively
abrogated IL-17A expression from WCA-stimulated splenocytes,
such that there was no detectable increase in IL-17A production
compared to splenocytes stimulated with medium alone; repletion
of CD4+ T cells restored the IL-17A response seen with
nondepleted splenocytes stimulated with WCA (Figure 2C).
Moreover, intracellular cytokine staining experiments confirmed
that IL-17A production originates primarily from CD4+ cells
(Figure 2D). Splenocytes from WCV-immunized animals were
stimulated with WCA and analyzed by flow cytometry. The
frequency of IL-17A positive cells increased 2.3 fold among CD4+
T cells (3.37% in WCA stimulated cells vs. 1.49% in cells
stimulated with medium alone, P = 0.008 by Mann-Whitney U)
whereas the non-CD4+ population was unaffected (1.5% vs. 1.7%
for stimulation with WCA vs. medium alone in CD4- cells,
P = 0.5). Similar analyses were performed using splenocytes from
mice immunized with CT alone; no increase in IL-17A positive
cells was noted, either in the CD4+ or CD4- population (data not
shown). Collectively, these results indicate that IL-17A is produced
by CD4+ T cells.
Next, we harvested nasal associated lymphoid tissue (NALT)
from WCV- and CT-immunized mice. Cells were incubated for 3
days in the presence of medium alone or with WCA, after which
IL-17A expression was measured by ELISA. NALT cells from
WCV-immunized mice showed significantly greater IL-17A
production than CT controls in response to stimulation with
WCA (Figure 2E).
To test whether the capacity to produce IL-17A predicted an
individual mouse’s protection, a total of 90 mice were intranasally
immunized with CT (1 mg) plus a range of doses of WCA ranging
from 1 to 100 mg and blood samples were taken 7 days before
challenge and stimulated with WCA in vitro for IL-17A production.
The IL-17A concentrations following 6 days of culture in vitro
varied from undetectable (,0.02 ng/ml) to about 6 ng/ml, and
the cfu of pneumococci/nasal wash 7 days post-challenge varied
from undetectable (,1.6 cfu/nasal wash) to about 3000; there was
a strong inverse correlation (Spearman r=20.62, P ,0.0001,
Figure 3); 95% of mice with pre-challenge IL-17A concentrations
above 0.3 ng/ml were free of pneumococcal colonization.
Neutrophil-like cells are required for acquired immunity
to pneumococcal carriage
Because IL-17 A induces neutrophil recruitment and activation
[23], we evaluated whether neutrophils were required for
protection against colonization. Mice intranasally immunized with
WCV (or CT alone) were challenged, with or without adminis-
tration of monoclonal antibody RB6-8C5 (which targets neutro-
phil-like cells) at the time of challenge. Several experiments were
performed to ensure that treatment with this antibody did not
affect CD4+ T cell number or function. Evaluation of splenocytes
of antibody-treated animals showed no reduction in the CD4+ T
cell population (data not shown). Furthermore, we confirmed that
IL-17A production from the peripheral blood or from NALT of
WCV-immunized mice was not affected by treatment with RB6-
8C5 antibody. The peripheral blood IL-17A expression from
immunized, neutrophil-depleted mice was similar to that of
immunized, nondepleted mice (median IL-17A whole blood
expression in neutrophil depleted vs. non-depleted mice: 1059
vs. 1290 pg/ml, P = 0.7 by Mann-Whitney U test); similarly, there
was no reduction in NALT IL-17A expression from immunized
mice following neutrophil depletion (median IL-17A expression
from NALT in depleted vs. nondepleted mice 23.6 vs. 19.8 pg/ml,
P = 0.69 by Mann-Whitney U test).
Neutrophil depletion significantly diminished protection by
immunization (Figure 4A). WCV-immunized and neutrophil deplet-
ed mice had both higher proportion of colonized mice (9/14 vs. 3/15
colonized mice for neutrophil-depleted vs. non-depleted WCV-
immunized mice respectively, P = 0.025 by Fisher’s Exact test) and
density of colonization (median 12.8 cfu/nasal wash vs. 0.8 cfu/nasal
wash respectively, P = 0.05 by Mann-Whitney U). While WCV-
immunized, neutrophil-depleted mice had reduced colonization
density compared to mice that received CT alone (median
colonization density 453 cfu/nasal wash, P = 0.006 by Mann-
Whitney U), the percentage of remaining neutrophils was strongly
negatively correlated with recovered cfu from challenged mice
(Spearman r=20.77, P = 0.001, Figure 4B), suggesting that residual
protection was accounted for in large part by incomplete neutrophil
depletion.
IL-17A and Pneumococcal Colonization
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Figure 2. Role of T-helper-subset-associated cytokines in protection from nasopharyngeal colonization. A. Mice defective in IFN-c, IL-4
or IL-17A receptor were immunized as described, then challenged with pneumococcal strain 0603. Mice with IFN-c or IL-4 deficiency were
significantly protected by WCV (P,0.001 vs. respective CT controls) whereas IL-17A receptor deficient mice were not protected (P.0.5 vs. CT).
Dashed line represents the lower limit of detection of bacterial colonization. B. Expression of IL-17A from splenocytes of WCV-immunized mice.
Cultured splenocytes from mice immunized with WCV (black columns) or CT alone (white columns) were stimulated for 72 hours with medium alone,
Concanavalin A (5 mg/ml), WCA (10 mg dry weight) after which IL-17A production was measured by ELISA. Significantly more IL-17A was expressed
following WCA stimulation of WCV-immunized vs. CT-immunized mice, although response to concanavalin A was similar. C. Effect of CD4+ T cell
depletion upon IL-17A expression from splenocytes. Splenocytes (without or with CD4+ T cell depletion) from mice immunized with WCV were
stimulated for 72 hours with medium alone or WCA after which IL-17A was measured by ELISA. IL-17A expression in splenocytes following WCA
stimulation was significantly higher in the presence of CD4+ T cells compared to stimulation with medium alone or when CD4+ T cells were depleted.
Repletion of CD4+ T cells restored the response. ** P,0.01 compared to cells stimulated with medium alone. D. IL-17A intracellular staining of
splenocytes from WCV immunized mice. Splenocytes from WCV immunized mice were stimulated with WCA, blocked with monensin, harvested and
IL-17A and Pneumococcal Colonization
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Consistent with these results, blinded review of histopathology
of nasopharyngeal tissue of 6/8 WCV-immunized mice seven days
after challenge with pneumococcus showed a distinct neutrophilic
infiltrate in the submucosa at the junction of the olfactory and
respiratory epithelium (Figure 4C, right panel), which is not seen
in CT-immunized subsequently challenged with pneumococci (left
panel) (presence of infiltrate in 6/8 WCV immunized mice vs. 0/7
CT controls, P = 0.007). Thus the data support a role for IL-17A
acting upon neutrophils in protection against pneumococcal
colonization in mice.
IL-17A expression in human samples following
pneumococcal stimulation
Next we determined whether IL-17A responses to pneumococ-
cus could be measured in humans. Tonsillar mononuclear cells
(from 8 donors) were stimulated with medium alone, WCA
obtained from a pneumolysin-negative strain (WCA(ply-)) or WCA
from the wild-type strain. IL-17A expression measured at 72 hours
was significantly higher following stimulation with WCA than with
medium alone (Fig 5A); this increase was abrogated when a
pneumolysin-negative WCA was used as stimulus, consistent with
prior findings in humans and in mice regarding the association
between T cell-mediated responses to this toxin and prevention of
pneumococcal colonization ([24] and unpublished data). Further-
more, whole blood from unimmunized adult human volunteers,
presumed to have been naturally exposed to pneumococcus,
produced IL-17A in response to WCA in vitro (Fig 5B). Eighteen
subjects produced a range of IL-17A concentrations from about 4
to 200 pg/ml, with a geometric mean of 20 pg/ml. Of these
volunteers, 11 were parturient women, whose geometric mean IL-
17A expression was 18 pg/ml. Umbilical cord blood was available
in each of these cases; IL-17A in these samples was at the lower
limit of detection of the assay (4 pg/ml) in all but one case,
significantly lower than that of all adult subjects or parturient
women (P,0.001 and P,0.01, respectively by Mann-Whitney U).
IL-17A enhances in vitro phagocytic killing of
pneumococci
We evaluated whether IL-17A enhances in vitro killing of
pneumococci by human neutrophils in different assays. Having
reported previously that WCV induced protection in antibody-
deficient mice, we developed a surface phagocytic killing assay to
evaluate whether -17A could potentiate killing of non-opsonized
pneumococci. Neutrophils isolated from healthy volunteers were
pre-incubated with recombinant human IL-17A, then overlaid on
pneumococci that had been plated onto blood agar. The overlay of
IL-17A in the absence of neutrophils did not result in any killing,
consistent with studies in which the addition of IL-17A to culture
medium did not affect growth of pneumococci and arguing against
any direct killing effect of the cytokine or contaminant present in the
preparation (as shown in Figure 6B). In the presence of neutrophils,
IL-17A induced dose-dependent killing of pneumococci (Figure 6A).
Thus IL-17A potentiated in vitro neutrophil killing of pneumococcus,
in the absence of antibodies or complement.
To evaluate whether the potentiating effect of IL-17A is the
result of lysis or degranulation of neutrophils, we performed trypan
blue exclusion studies of neutrophils with and without preincuba-
tion with IL-17A at the highest dose studied (10 mg/ml). There
was no difference in viability when IL-17A was added; over 95%
of cells remained viable after 30 minutes of incubation. Further-
more, neutrophils preincubated with IL-17A then washed showed
the same enhancement of pneumococcal killing as incubated
neutrophils that were not washed. In contrast, the supernatant
obtained after incubation of neutrophils and IL-17A had no
detectable antipneumococcal activity (Figure 6B). Taken together,
these data argue against a toxic or degranulating effect of IL-17A
on neutrophils and are more consistent with enhancement of
phagocytic activity of neutrophils by this cytokine.
Because capsular and noncapsular antipneumococcal antibodies
gradually increase with age in children [6,25,26], we also evaluated
whether IL-17A would potentiate opsonophagocytic killing of S.
pneumoniae in the presence of limiting amounts of antibody. Bacterial
polysaccharide immune globulin (BPIG) is a plasma concentrate from
volunteers immunized with bacterial polysaccharides including
pneumococcal serotype 6B [27]. To evaluate whether IL-17A would
synergize with antipneumococcal antibodies, we added IL-17A to an
opsonophagocytic assay using a suboptimal dose of BPIG. When IL-
17A was added to the reaction, killing of pneumococcus was
enhanced in a dose-dependent fashion in all individuals tested
(Figure 6C). Killing was significantly increased when either 1 mg or
10 mg/ml IL-17A were added (P = 0.016 by Wilcoxon matched pairs
test). There was no significant pneumococcal killing in the assay in the
absence of any of the principal components, including PMNs,
antibody (BPIG) or complement (data not shown). Additionally, as in
the surface phagocytosis assay, IL-17A alone had no effect on growth
of bacteria in vitro or survival in our assay, implying that direct killing
of pneumococci by IL-17A is very unlikely.
Figure 3. Correlation of IL-17A expression and density of
nasopharyngeal colonization in mice. Three weeks after immuni-
zation of mice (n = 90) with CT with doses of WCA ranging from 1 to
100 mg, and one week before pneumococcal challenge, blood samples
were obtained and stimulated with WCA (10 mg) for 6 days, after which
supernatants were collected and assayed for IL-17A concentration. The
correlation between density of colonization (cfu/nasal wash) 7 days
after challenge and pre-challenge IL-17A expression was evaluated. IL-
17A expression was significantly correlated with density of colonization.
doi:10.1371/journal.ppat.1000159.g003
stained for CD4+ and intracellular IL-17A as described. There is a statistically significant increase in CD4+ IL-17A positive cells following stimulation
with WCA, which is not observed in the CD4- population. No increase in IL-17A positive cells could be detected in cells from unimmunized mice (data
not shown). **P = 0.008 for comparison of frequency of IL-17A-positive cells in absence and presence of WCA stimulation among CD4+ cells. Data
shown here are representative of three experiments, including at least 5 mice per experiment. E. Expression of IL-17A from NALT of WCV- vs. CT-
immunized mice. Cultured splenocytes from mice immunized with WCV (black columns) or CT alone (white columns) were stimulated for 72 hours
with medium alone or with WCA (10 mg dry weight) after which IL-17A production was measured by ELISA. Significantly more IL-17A was expressed
following WCA stimulation of WCV-immunized vs. CT-immunized mice. **P,0.01 for comparison of IL-17A in WCV vs. CT-immunized mice following
stimulation with WCA.
doi:10.1371/journal.ppat.1000159.g002
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Discussion
The importance of CD4+ T cells in protection against
pulmonary infections became clearly evident with the advent of
the HIV epidemic. Infected individuals have a dramatically
increased risk of infections with opportunistic pulmonary patho-
gens such as Mycobacterium tuberculosis or Pneumocystis jiroveci and this
risk is inversely related to the number of circulating CD4+ T cells
Figure 4. Effect of neutrophils on WCV-induced protection against pneumococcal colonization. A. Effect of neutrophil depletion on
WCV-induced protection from nasopharyngeal colonization. Each data point represents the density of nasopharyngeal colonization in cfu/nasal wash
for each mouse. The horizontal bar shows the geometric mean cfu/nasal wash for each group and the dashed line shows the lower limit of detection
of bacterial colonization. Mice were immunized with CT or WCV as indicated; just prior to the time of challenge, mice were randomized to receive
antineutrophil antibody vs. saline. Proportion of colonized mice and density of colonization was determined 7 days post challenge. WCV-immunized
mice that received saline treatment were significantly better protected than WCV-immunized mice that received antineutrophil antibody, with a
lower proportion of colonized mice (P = 0.025 by Fisher’s Exact) and density of colonization (P = 0.05 by Mann-Whitney U). B. Correlation between
neutrophil count and density of pneumococcal colonization. Neutrophil counts following neutrophil depletion were assayed at the time of sacrifice
and plotted against density of colonization. There was a strong negative association between neutrophil counts and colonization density (Spearman
r=20.75). C. Histopathology of nasopharyngeal tissue following nasopharyngeal challenge of CT- (left panel) and WCV-immunized (right panel)
mice. Seven days post pneumococcal challenge, mice were euthanized, heads stored in formalin, and H&E sections of nasopharyngeal tissue
prepared and examined under light microscopy at 606magnification. The presence of a dense neutrophilic infiltrate in the submucosa at the
junction of the olfactory and respiratory epithelium was noted in WCV-immunized mice following pneumococcal nasopharyngeal challenge but not
in CT-immunized mice. The two slides shown are representative of a total of 15 examined specimens (8 WCV-immunized and 7 CT controls, all at day
7 post pneumococcal challenge). Lesions like those represented here were observed in 6/8 immunized mice and 0/7 controls.
doi:10.1371/journal.ppat.1000159.g004
IL-17A and Pneumococcal Colonization
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[28,29]. For S. pneumoniae, HIV infection confers a 50-fold
increased risk of infection, which is also inversely related to
CD4+ T cell count [30,31]. Most recently, a study in Zambian
mothers has demonstrated that HIV infection is associated with a
significantly increased risk of colonization and reduced time to
new colonization [32]. Various hypotheses have been advanced to
explain why CD4+ T cell-deficiency is associated with such a high
risk of infection with pneumococcus, a primarily extracellular
encapsulated bacterium; these include reduced opsonic activity of
anticapsular antibodies [33], loss of memory B cells [34], and
alteration of innate pulmonary immunity [35]. To date, however,
it is fair to state that the paradox remains unexplained. The data
presented here suggest that a loss of TH17 cells may also
contribute to this increased susceptibility.
While the ability of pneumococcal conjugate vaccine-induced
anticapsular antibodies to protect against pneumococcal coloni-
zation is clear, less is known about the natural development of
immunity to pneumococcal colonization. There appear to be both
antibody-dependent and antibody-independent mechanisms that
reduce the likelihood or duration of carriage. Several studies have
documented a homotypic anticapsular serum antibody response to
colonizing pneumococcal serotypes [4,36,37,38]. In a longitudinal
study examining the relationship between antibodies and carriage
Figure 5. Effect of exposure to pneumococcus on IL-17A
expression from human tissues and cells. A. Expression of IL-
17A from tonsillar mononuclear cells from children. Tonsillar cells (n = 8)
were cultured as described and stimulated with WCA or WCA derived
from an isogenic, pneumolysin-negative strain (WCAply-). Stimulation
with WCA was associated with significantly increased IL-17A expression
compared to exposure to medium alone (P = 0.008 by Wilcoxon signed
rank test), whereas stimulation with WCAply- did not increase IL-17A
production. B. Expression of IL-17A from peripheral blood of adults and
umbilical cord blood. Peripheral blood samples from adults (healthy
adult volunteers (n = 7), parturient women (n = 11) and umbilical cord
blood (n = 11) were stimulated with WCA for 6 days after which IL-17A
concentration was assayed by ELISA. IL-17A production was signifi-
cantly greater in adults than cord blood (P,0.001 by Mann-Whitney U
test).
doi:10.1371/journal.ppat.1000159.g005
Figure 6. IL-17A-mediated enhanced killing of S. pneumoniae. A
and B. Effect of human IL-17A on surface phagocytic killing of S.
pneumoniae. A. Isolated neutrophils from healthy adult volunteers were
incubated with recombinant human IL-17A at the indicated concen-
trations and evaluated in a surface phagocytic killing assay with
pneumococcal strain 0603; colonies were counted after overnight
incubation at 37uC with 5% CO2. IL-17A induces a dose-dependent
enhancement of neutrophil killing of S. pneumoniae (P = 0.01 for 1 or
10 mg of IL-17A vs. no added IL-17A). B. Supernatant obtained from
neutrophils after incubation with IL-17A did not have any demonstrable
antipneumococcal effect, whereas washed neutrophils after incubation
with IL-17A demonstrated enhanced killing. C. Effect of human IL-17A
on opsonophagocytic killing of S. pneumoniae. Neutrophils purified
from the peripheral blood of healthy adult volunteers were incubated
with pneumococci anticapsular antibodies, complement, and a range of
concentrations of IL-17A as indicated for 90 minutes, following which
viable counts were obtained by plating on blood agar plates. Each line
represents a different volunteer. IL-17A enhanced killing of pneumo-
cocci in a dose-dependent fashion in 6/6 subjects. *P = 0.016 by
Wilcoxon matched pairs test.
doi:10.1371/journal.ppat.1000159.g006
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in adults, Goldblatt et al. showed that, among six serotypes tested,
anticapsular antibody concentration to serotype 14 was significantly
associated with reduced odds of carriage [4]. More recently, by
analyzing longitudinal carriage data from Israeli toddlers in
daycare, we found a lower risk of colonization with type 6A, 14,
and 23F after previous exposure to the homologous type [5]. For
types 14 and 23F, this specific protection correlated with increased
serotype-specific antibody concentration. On the other hand, as in
the previous study [4], there was no evidence for such a correlation
with several other serotypes. Several studies have argued against the
role of anticapsular antibody. For example, the risk of acquisition of
new pneumococcal strains in adults with chronic obstructive
pulmonary disease was associated with higher preacquisition
concentrations of anticapsular and noncapsular pneumococcal
antibodies [11]. These results suggest that in this population,
antipneumococcal antibodies are markers of prior exposure and
perhaps greater susceptibility rather than predictors of protection.
Finally, in the sole published example of experimental pneumococ-
cal colonization of humans, antibodies to the capsular polysaccha-
ride did not predict protection against colonization [39].
We, and others, have presented data supporting a role of CD4+
T cells, independently of antibody, in reducing pneumococcal
colonization in mouse models [18,19,20,22,40]. In studies
involving immunization with the pneumococcal zwitterionic
conserved cell wall polysaccharide, we showed that neutralization
of IL-17A significantly reduced protection, albeit not completely
[21]. Zhang et al. then showed that reduced CD4+ T cell
proliferative responses to the pneumococcal toxin pneumolysin
were associated with nasopharyngeal pneumococcal carriage in
children [24]. We subsequently showed that immunization with a
mixture of a pneumolysin nontoxic mutant and two other
pneumococcal proteins elicits TH17 cells and confers protection
against colonization in a CD4+ T cell-dependent, antibody-
independent fashion [22]. Others have argued against this
possibility, proposing instead a TH1, IFN-c mediated mechanism,
based on the finding that IL-12p40-deficient mice cleared
pneumococcal colonization as well as wild-type mice [20]. Since
that report, it has become clear that IL-23, which is lacking in IL-
12p40 deficient mice, is not absolutely required for the generation
of TH17 cells as once was thought, but instead participates in their
maintenance or expansion [41,42].
Here we present evidence that acquired CD4+ TH17 cells reduce
the duration of experimental colonization with S. pneumoniae in a
manner reminiscent of the age-dependent decline in duration of
carriage [7] and that this mechanism occurs independently of key
TH1 or TH2 cytokines, IFN- c and IL-4 respectively. We show that
CD4+ T cells are sufficient to provide the protection against
colonization, which is abrogated in the absence of the IL-17A
receptor and highly dependent on neutrophils, one of the main
targets of this cytokine. Recombinant human IL-17A enhances both
antibody-independent and –dependent killing of S. pneumoniae in
vitro. Importantly, IL-17A expression can be induced by exposure to
pneumococcal antigens of tonsillar cells from children and
peripheral blood from healthy adult volunteers, but not in umbilical
cord blood, consistent with the view that this responsiveness may be
the result of prior exposure to the pathogen.
IL-17A signaling been shown to participate in host defense
against extracellular pathogens, such as Klebsiella and Candida in
naı¨ve mice [43,44]. Prior to this report, there have been two
demonstrations of a role of TH17 cells in vaccine-induced
immunity and in both cases, whole organisms, killed or live, were
used. Higgins et al. showed that protection against Bordetella
pertusssis with a whole cell vaccine induced TH17-dependent
protection and Khader et al. presented similar findings with the
mycobacterial protein ESAT6-induced protection against M.
tuberculosis [45,46,47]. The data derived from both mouse and
human studies in the present report thus add to the growing
evidence that TH17 cells contribute to immunity to respiratory
pathogens.
Numerous attempts have been made to define correlates of
protection against pneumococcal carriage and have focused on the
humoral response to pneumococcal capsular or noncapsular
antigens [4,15,48]; although associations between levels of
antibodies in saliva and reduced risk of otitis media have been
reported [48], no reliable correlate has been identified. Here we
show that the IL-17A response in immunized mice is highly
correlated with reduced carriage; in particular above a certain
concentration, colonization beyond 7 days is very unlikely.
Naturally-exposed humans have low, but measurable IL-17A
responses, which could be evaluated in response to immunization
with candidate pneumococcal vaccines, such as the whole cell
vaccine currently under development. The demonstrated associ-
ation between carriage and reduced T cell proliferative responses
to pneumolysin in childhood [24] provides further support for a
functional T cell assay such as the one proposed here.
Materials and Methods
Bacterial strains and immunogens
S. pneumoniae strain 0603 is a serotype 6B clinical strain [49].
Frozen mid-log phase aliquots were diluted to ,106 cfu/10 ml of
intranasal inoculum for challenge. The whole cell antigen (WCA)
was derived from strain Rx1AL-, a capsule- and autolysin-negative
mutant and prepared as described [49]. A pneumolysin-negative
WCA (WCA(ply-)) was derived from an isogenic, pneumolysin-
negative strain of Rx1AL- using methods previously described
[18]. The final vaccine mixture (whole cell antigen WCA +
adjuvant CT) for routine immunization contained 100 mg (dry
weight) of WCA plus 1 mg of CT (List Biological Laboratories,
Campbell, CA) per 10 ml dose. For potency comparisons, lower
amounts of WCA were used (ranging from 0.1 mg to 10 mg). For
all experiments, control mice were immunized nasally with 1 mg of
CT in 10 ml saline.
Animal models
The animal model used in these experiments has been
previously described [49]. C57BL/6J mice or mutants in the
same background (female, age 6 weeks, Jackson Laboratories, Bar
Harbor, ME) were randomized to receive 10 ml of whole cell
vaccine or adjuvant alone intranasally twice at one week interval.
Three weeks following the last inoculation, mice were anesthetized
for retro-orbital blood sampling. One week later, mice were
challenged intranasally with ,106 cfu of strain 0603. At 1 week
after challenge, the mice were euthanized by CO2 inhalation; an
upper respiratory wash was done by instilling sterile, nonbacterio-
static saline retrograde through the transected trachea and
collecting the first 6 drops (about 0.1 ml) from the nostrils.
Following collection of nasopharyngeal samples, the heads of
WCV- and CT-immunized mice were removed and placed in
formalin prior to histopathological preparation with hematoxylin
and eosin (H&E) staining.
To evaluate the time to eradication of carriage, in a separate
experiment, 4 mice from groups of 16 each were sacrificed at 1, 2,
4 and 6 days post inoculation and sequential dilutions of nasal
washes were plated. To test whether CD4+ T cells are sufficient
for protection, adoptive transfer experiments were performed.
Splenocytes from wild type C57Bl/6 mice immunized with WCV
or CT alone were harvested 2 months after the last immunization
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and CD4+ T cells were purified by magnetic bead positive
selection (Miltenyi Biotec, Auburn, CA). A total of 36106 CD4+ T
cells were injected retro-orbitally in naı¨ve RAG12/2 mice
(B6.129S7-Rag1tm1Mom/J) that lack both B and T cells. The
following day, these mice were challenged intranasally with strain
0603; one week later, density of colonization was determined as
described above.
To determine which T cell subset is responsible for protection,
mice in the C57BL/6 background and deficient in IFN-c
(B6.129S7-Ifngtm1Ts/J, Jackson Laboratories, Bar Harbor, ME)
IL-4 (B6.129P2-Il4tm1Cgn/J, Jackson Laboratories) or the IL-17
receptor (B6.129 IL17Ra2/2 [50]) were immunized and chal-
lenged as described above. For neutrophil depletion experiments,
mice were immunized as described above; on days 21, +1 and +4
relative to challenge, mice were injected intraperitoneally with
100 mg of antineutrophil monoclonal antibody RB6-8C5 (purified
from myeloma cell line by Bio Express, Lebanon, NH), a rat anti-
mouse IgG2b directed against Ly-6G on the surface of murine
myeloid (and limited subpopulations of lymphoid) lineage cells; in
pilot experiments, this regimen resulted in .90% depletion of
neutrophils in most mice, although variability was observed.
Because of this variability, peripheral neutrophil counts were
determined at the time of euthanasia and correlated with the
number of recovered pneumococci from that animal.
Measurement of IL-17A secretion by splenocytes
Cellular suspensions of splenocytes were obtained by passing
spleens from immunized or control mice through a 70-mm cell
strainer (BD Biosciences, Bedford, MA). After washing and
removal of red blood cells by hemolysis, cells were plated into
24-well tissue culture plates at a concentration of 56106 cells/well
in 500 ml of DMEM/F12 with L-glutamine supplemented with
10% fetal calf-serum, 50 mM 2-mercaptoethanol (Sigma), and
10 mg/ml ciprofloxacin. Following 72-hour stimulation with
concanavalin A (5 mg/ml, Sigma) or WCA (equivalent to
106 cfu/ml), supernatants were collected following centrifugation
and stored at 280uC until analyzed by ELISA for IL-17A
concentration (R&D Systems, Minneapolis, MN). Supernatants
were analyzed in duplicate and read against a standard, following
directions provided by the manufacturer.
For CD4+ T cell depletion, splenocytes were harvested as
described above. CD4+ T cells were depleted from half of each
spleen by magnetic bead selection (Miltenyi Biotec, Auburn, CA)
following instructions by the manufacturer. Flow cytometry
confirmed removal of .95% CD4+ T cells (data not shown).
Cells were seeded at the same concentration as described above
(56106 cells/well). In some cases, we repleted CD4+ T cells from
depleted splenocytes, by adding 106 CD4+ T cells in the relevant
wells.
Intracellular staining for IL-17A
Splenocytes were harvested, seeded, and stimulated with
medium or WCA (10 mg/ml) as described above. Twenty-four
later, monensin (BD GolgiStop, BD Biosciences) was added as per
the manufacturer’s instructions and cells were harvested 12 hours
later. Cells were washed, stained with anti-CD4+ antibody
(antiCD4+-PE, BD Biosciences) in the presence of Fc block,
permeabilized with Perm/Wash buffer (BD Biosciences), and
incubated with antimouse IL17A Alexa Fluor-647 (eBioscience)
for 30 minutes. Intracellular cytokine staining for IL-17A was
compared in CD4- or CD4+ cells in medium alone or following
stimulation with WCA. Samples were analyzed on a Cytomation
MoFlo (Beckman Coulter, Fullerton, CA), and results analyzed
with Summit Version 4.3 (Dako, Fort Collins, CO).
Measurement of IL-17A secretion by NALT
NALT was harvested from immunized and control mice as
described [51]. Mice were euthanized humanely, bled via
intracardiac puncture to avoid blood contamination, and placed
on a dissection board. The mouth was opened wide to expose the
palate, which was cut carefully, so that the strips of NALT could
be easily peeled off. These strips of cells were collected in medium
(DMEM/F12 with L-glutamine supplemented with 10% fetal calf-
serum, 50 mM 2-mercaptoethanol (Sigma), and 10 mg/ml cipro-
floxacin) on ice. Cells were passed through a 70 mm strainer as
described above and plated at 36105 cells/well in a 96-well tissue
culture plate in a total volume of 100 ml. Cells were stimulated
with medium with or without added WCA (10 mg/ml) for a total
of 3 days, after which supernatants were collected and assayed for
IL-17A concentration by ELISA as above.
Measurement of IL-17A secretion by whole blood
For whole blood assays, blood of mice or humans at a final
concentration of 10% was incubated in DMEM/F12 with L-
glutamine supplemented with 10% fetal calf-serum, 50 mM 2-
mercaptoethanol (Sigma), and 10 mg/ml ciprofloxacin in the
absence or presence of killed pneumococcal antigen (correspond-
ing to 107 cfu/ml for mice and 106 cfu/ml for human samples).
Supernatants were collected after 6 days and the concentration of
IL-17A measured as above for mice and, for human samples, by
IL-17A ELISA (eBioscience Inc, San Diego, CA).
Human subjects and samples
For peripheral blood, samples were obtained at Children’s
Hospital Boston (for healthy adult volunteers) or from Cambridge
Health Alliance, Cambridge, MA (for parturient women or
umbilical cord) after written informed consent had been obtained.
The studies were approved by the Children’s Hospital Boston and
Cambridge Health Alliance research ethics committees. For
tonsillar specimens, tonsils were obtained from children who were
2 to 12 years old (median age, 5 years), were undergoing
tonsillectomy for hypertrophy, and were otherwise healthy at
Bristol Royal Hospital for Children, Bristol, United Kingdom.
Patients who were immunized against pneumococcus previously,
who had received antibiotics within 2 weeks of the operation or
steroids, or who had an immunodeficiency or serious infection
were excluded. The study was approved by the South Bristol local
research ethics committee and written informed consent was
obtained in all cases.
Agar surface phagocytic killing without opsonins
This assay approximates the ‘‘surface phagocytosis’’ described
by Smith and Wood [52]. Neutrophils were isolated from
heparinized blood by density gradient centrifugation (Histopaque,
Sigma) following manufacturer’s instructions. Neutrophils were
washed extensively then resuspended in Hanks’ Balanced Solution
(+ Ca2+ and Mg2+) with 0.2% bovine serum albumin (Sigma), then
co-incubated for 30 minutes at 37uC with recombinant human IL-
17A (R&D Biosystems) at different concentrations. In some
experiments, the cells were harvested by centrifugation and the
supernatant collected, to examine whether the potentiating effect
of IL-17A could be detected with the supernatant alone. Between
8–10 replicates of 10 ml of a bacterial suspension containing on
average 100 cfu of strain 0603 were plated onto blood agar and
the fluid allowed to adsorb into the agar for 15 min; 15 ml of the
neutrophil suspension was overlaid and allowed to adsorb; the
plates were incubated at 37uC with 5% C02 overnight after which
colonies were counted.
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Phagocytic killing in suspension with suboptimal
opsonization
Neutrophils were isolated from whole blood as described above,
washed twice with cold Hanks Balanced Salt Solution (HBSS-)
(Mediatech, Herndon, VA), and resuspended to a final concen-
tration of 66106 cells/ml in cold HBSS containing calcium and
magnesium (HBSS+) (Cellgro Mediatech, Herndon, VA) then held
on ice until used. Cell counts were determined on a standard
hemocytometer by counting viable cells (as determined by an
absence of blue staining in the presence of Trypan Blue (Cellgro
Mediatech, Herndon, VA)). S. pneumoniae (strain 0603 [49]) was
diluted in HBSS+ to a final concentration of 56104 bacteria/ml
and incubated with antibodies to pneumococcal polysaccharide
(Bacterial Polysaccharide Immune Globulin, BPIG-8, a kind gift of
Dr. George Siber, consisting of concentrated IgG obtained from
serum of adult volunteers immunized with pneumococcal,
Haemophilus and meningococcal polysaccharide vaccines [27])
diluted in HBSS+. The reaction was incubated at 37uC for
15 minutes rotating at 200 RPM to promote bacterial opsoniza-
tion. After bacterial opsonization, the opsonophagocytic killing
reaction was initiated with the addition of baby rabbit complement
(Pelfreez Biologicals, Rogers, AR) and neutrophils (ratio of 1:200
bacteria:cells) with or without recombinant human IL-17A (R&D
Systems, Minneapolis, MN) at 0.01, 0.1 or 1 mg/ml. A 1:1600
dilution of BPIG was chosen to give sub-optimal bacterial killing
(,50% killing when compared to the same conditions without
BPIG) in the presence of complement and neutrophils. The
opsonophagocytic killing assay was performed in a 96-well round-
bottom plate (Thermo Fisher Scientific, Waltham, MA) at 37uC
for 90 minutes rotating at 200 RPM. After incubation, the
opsonophagocytic reaction was diluted two fold and aliquots of
each reaction were plated on blood agar plates then incubated at
37uC with 5% CO2 overnight.
Isolation and culture of tonsillar mononuclear cells
Mononuclear cells were isolated by using methods described
previously [53,54]. Tonsillar MNC were washed in sterile
phosphate-buffered saline (PBS) and resuspended at a concentra-
tion of 46106 cells/ml in RPMI medium containing HEPES,
2 mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin,
and 10% fetal bovine serum (Sigma, Dorset, United Kingdom).
Cells were cultured in 96-well culture plates (Corning Inc,
Corning, NY), and cell culture supernatants were collected at
predetermined times and stored at 270uC until assays for human
IL-17A were performed by sandwich ELISA (R&D Biosystems).
Statistical analysis
Incidence of carriage was compared by Fisher’s exact test and
colonization density in challenged mice was compared by the
Mann-Whitney U test. Statistical significance of the difference
between time-to-clearance curves was assessed as follows. For each
group i (i= WCV, CT, live, or naı¨ve), the proportion of mice
cleared at each time point t, pi(t), was calculated. Using the max-
min formula for isotonic regression [55], these proportions were
smoothed to assure they were nondecreasing in t, yielding
smoothed proportions qi(t). Then, a test statistic was calculated
to quantify the distance between the smoothed curves for two
groups (e.g., WCV vs. CT): T~
P
t
qWCV tð Þ{qCT tð Þ½ 2. The
significance level of this test statistic was estimated by permuting
the group identifiers of the cleared mice at each time point, fixing
the total number of mice in each group and the total number
cleared at each time point. 100,000 replicates of the permuted
data were obtained, and T was calculated for each. The p value
was calculated as the fraction of these 100,000 permutations
having a test statistic strictly less than that calculated for the data.
The correlation between neutrophil count or IL-17A concentra-
tion and colonization density was determined by Spearman rank
correlation. The effect of increasing IL-17A concentrations on
enhancing killing of pneumococcus was assessed by Wilcoxon
matched pairs test. For all comparisons, P,0.05 was considered to
represent a significant difference.
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